By recognizing these synergistic effects between immune markers, future strategies could combine PD-1/PD-L1 inhibitors with treatments that enhance T-cell infiltration or relieve other immunosuppressive mechanisms, thereby potentiating the overall anti-tumor immune response. Here, CD274 is linked to neoplasm.